{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"39","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.\n\nlenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.","id":"OG000","title":"Lenalidomide and Azacitidine"}],"paramType":"MEDIAN","populationDescription":"Only patients with a complete response were analysed","reportingStatus":"POSTED","timeFrame":"After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months","title":"Time to Relapse After Achieving Complete Response","type":"SECONDARY","unitOfMeasure":"months"}